For Boston Scientific, a potential threat
236748
Boston Scientific Corp. could face tougher competition in markets for cardiac products if talks between two of its largest competitors lead to a merger, analysts and investors said.
262318
A software developer whose program was accidentally labeled a threat is considering action against the antivirus company.
764674
Boston Scientific Corp. found a slightly higher risk of blood clotting in patients implanted with its newer drug-coated stents compared with older bare-metal versions, a company spokesman said Thursday.
290938
Boston Scientific Corp. BSX.N on   Thursday said an internal analysis confirmed an increased risk   of blood clots with its drug-coated device used to keep   previously clogged arteries open.
174973
At Lawrence Livermore lab in northern  California and other national labs, U.S. scientists are hard at  work devising new inventions to monitor unlikely but horrific  dangers that could stem from future terrorist attacks.
565353
If Biogen Idec Inc. is sold to a pharmaceuticals giant, as many biotech industry observers expect, it could spell the loss of yet another major corporate headquarters in Massachusetts, a blow to the state's prestige.
154676
Iconoclasts at heart, the best scientists are faced with an occupational hazard: having left their mark on one small patch of ground, they are tempted to stir up trouble elsewhere.
378482
These products don't come without serious risks.
205492
The three recalls of Boston Scientific Corp. cardiac stents since July 2 affected many more units than the company has previously disclosed, raising concerns among stock analysts about future inventory levels.
463269
October is in our sights, and the two important teams from Massachusetts are confounding the experts. It&#39;s the Red Sox baseball club, not the Kerry presidential campaign, that&#39;s supposed to be in its pre-autumn swoon.
517635
It may be too early to tell, but some Symantec partners have already begun to express concern.
253054
A jury in Texas has ruled that Boston Scientificâs drug-coated stents infringe a 1997 patent issued to a radiologist in Princeton, N.J., and has awarded the inventor $431 million in damages, Boston Scientific said Tuesday. The suit by the patent holder, Dr. Bruce N. Saffran, did not seek to halt sales of the stents.
174927
Pressure is building against the widely reported gifts and other potential conflicts between drug companies and doctors.
585742
Boston University confirmed that three researchers who fell ill last year had been exposed to a potentially lethal bacterium, and a local health official said the city should have been notified sooner.
110392
Warnings could be introduced after analysis confirms high levels of bacteria and viruses.
755292
An adverse panel recommendation could threaten Northgate Minerals' golden opportunity.
434277
The market might overlook the drug maker's promising programs.